Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T16:38:44.544Z.
Calculation as of: 2026-10-06T16:38:44.544Z.
Quote observation: 2026-10-06T16:34:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b1195b951add05ab4c37664b10382d427b1d38f05de7a164f71fe4d518fffb76
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$83.24M
Price/OCF Ratio
N/A
TTM Avg
17.74
3Y Avg
16.00
5Y Avg
17.53
Market Cap
$84.43M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$82.82M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$81.81M
Price/OCF Ratio
N/A
TTM Avg
786.57
3Y Avg
786.57
5Y Avg
786.57
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProMIS Neurosciences, Inc. (PMN) | $83.85M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.10M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $83.24M | N/A | 17.74 | 16.00 | 17.53 |
| LENSAR Inc (LNSR)vs › | $83.21M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.43M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $82.82M | N/A | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.45M | N/A | 111.15 | 111.15 | 111.15 |
| Nutriband Inc. (NTRB)vs › | $82.05M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $81.81M | N/A | 786.57 | 786.57 | 786.57 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $87.22M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
